Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains

NCT00556946 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2022-10-21

Study results available
· View outcomes & findings →

Summary

This research study was designed to determine the effect on port wine stains (PWS) of liposomal benzoporphyrin derivative monoacid (BPD-MA) termed verteporfin by intravenous (IV) infusion for photodynamic therapy (PDT) or combined PDT and pulsed dye laser (PDL) therapy (PDT + PDL). The standard treatment for PWS is PDL alone. This lightens some PWS but many lesions are not completely removed.

PDT uses a medication and light together to cause injury to a target. The medication is given and then light is directed at the desired area of treatment to achieve an effect. PDT has been used to treat some skin conditions including pre-cancers and skin cancers. Using PDT or PDT immediately followed by PDL therapy may improve PWS lightening. At this time, both PDT and PDT + PDL therapy for treatment of PWS is investigational. The type and amount of medication and light which may be used to treat PWS is not known, and is likely to be different than those used for other PDT treatments.

Conditions

  • Port Wine Stains

Interventions

DRUG

Combined Photodynamic & Pulsed Dye Laser Treatment

Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser

Sponsors & Collaborators

  • Beckman Laser Institute University of California Irvine

    collaborator OTHER
  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Kristen Kelly, MD · Beckman Laser Institute University of California Irvine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00556946 on ClinicalTrials.gov